Deutsche Bank lowers Merck KGaA price target to EUR133 on mixed Q2

Deutsche Bank lowered its price target on Merck KGaA (ETR:MRK) to EUR133.00 from EUR140.00 while maintaining a Buy rating, following the company's mixed second-quarter results. The firm cited the need for positive consensus earnings revisions, but expressed optimism for stabilization with upcoming third-quarter results after 2025 guidance adjustments. Despite investor frustration with Merck's group structure, Deutsche Bank sees over 20% upside potential from current levels, driven by attractive valuation and improving performance in the Life Science business.

Analysis

Deutsche Bank has revised its price target for Merck KGaA (ETR:MRK) downward to EUR133.00 from EUR140.00, a move prompted by the company's mixed second-quarter results and recent negative consensus earnings revisions. Despite this reduction, the bank maintains its 'Buy' rating, signaling a fundamentally positive outlook. The analysis suggests that Merck's 2025 guidance has been sufficiently de-risked, potentially setting the stage for stabilization with the upcoming third-quarter report. Deutsche Bank's investment thesis hinges on two key factors: an attractive valuation, with the new price target representing over 20% upside from current levels, and the improving performance of the company's critical Life Science business. While acknowledging investor frustration with Merck's complex group structure, the bank believes underlying value can still be unlocked within the existing corporate setup, presenting a contrarian opportunity.

Key Decisions for Investors

• Investors could consider the current share price an attractive entry point, given the maintained 'Buy' rating and a price target implying over 20% potential upside, especially for those bullish on the recovery of the Life Science sector.
• It is crucial to monitor the upcoming third-quarter results closely, as they are positioned as a key catalyst for potential earnings stabilization and a reversal of negative estimate trends.
• One should weigh the valuation-based opportunity against the identified risk of ongoing investor frustration with the corporate structure, which could remain a persistent overhang on the stock's performance until resolved or a clear value-unlock catalyst emerges.